Cubist Shares Rise 35% After Merck Agrees To Acquire Company For $9.5 Billion
December 08, 2014 at 18:38 PM EST
Later in the day, both stocks took a hit as a judge agrees that Hospira can market a generic version of Cubist's lead drug as early as 2016.
